Trastuzumab for gastric cancer treatment

The Lancet

Volumn 376, Issue 9754, 2010, Pages 1735-

  Fujita, Tetsuji ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADVANCED CANCER; ASIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DRUG APPROVAL; DRUG TOLERANCE; EUROPE; HUMAN; LETTER; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER;

EID: 78649341599     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)62125-3     Document Type: Letter

References (5)

1. YJ Bang, E Van Cutsem, A Feyereislova Trastuzumab in combination with chemotherapy versus chemotherapy alone for HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
2. AFC Okines, D Cunningham Trastuzumab in gastric cancer Eur J Cancer 46 2010 1939 1959
3. AJ Munro, PG Niblock Cancer research in the global village Lancet 376 2010 659 660
4. BBY Ma, EP Hui, TSK Mok Population-based differences in treatment outcome following anticancer drug therapies Lancet Oncol 11 2010 75 84
5. W Koizumi, H Narahara, T Hara S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 2008 215 221